^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Estrogen receptor agonist

8d
Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation (clinicaltrials.gov)
P4, N=120, Recruiting, University of Southern California | Trial completion date: Dec 2027 --> Jun 2028 | Trial primary completion date: Mar 2026 --> Jun 2028
Trial completion date • Trial primary completion date
29d
Trial completion
|
Orgovyx (relugolix)
1m
Mechanistic Insights into the Therapeutic Effects of Zishen Yutai Pill on Premature Ovarian Insufficiency via the RIPK1/RIPK3/MLKL Necroptosis Pathway. (PubMed, Comb Chem High Throughput Screen)
ZYP ameliorates CTX-induced POI by regulating hormones, improving ovarian morphology, and inhibiting the RIPK1/RIPK3/MLKL pathway.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1) • RIPK3 (Receptor Interacting Serine/Threonine Kinase 3) • MLKL (Mixed Lineage Kinase Domain Like Pseudokinase)
|
cyclophosphamide • estradiol valerate
1m
Impact of Estradiol on Endothelial Function in Peri-Menopausal Women (clinicaltrials.gov)
P4, N=80, Active, not recruiting, University of Delaware | Trial completion date: Jun 2026 --> Oct 2026 | Trial primary completion date: May 2026 --> Sep 2026
Trial completion date • Trial primary completion date
1m
Trial completion date
2ms
TeenVIBE: Teen Vulnerability to Irritability: Brain and Estrogen Changes (clinicaltrials.gov)
P4, N=50, Not yet recruiting, University of North Carolina, Chapel Hill
New P4 trial
2ms
PERT: Intravenous Estrogen in Kidney Transplant Study (clinicaltrials.gov)
P1/2, N=30, Active, not recruiting, University of Pennsylvania | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
Trial completion date • Trial primary completion date
2ms
HNF1595-21: Estrogen replacement therapy (ERT) for treatment of adolescent anorexiannervosa An open label study (2024-519908-27-01)
P1/2, N=36, Completed, Universitetssykehuset Nord-Norge HF | Not yet recruiting --> Completed
Trial completion